PL3407910T3 - Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni - Google Patents
Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koniInfo
- Publication number
- PL3407910T3 PL3407910T3 PL17702827.1T PL17702827T PL3407910T3 PL 3407910 T3 PL3407910 T3 PL 3407910T3 PL 17702827 T PL17702827 T PL 17702827T PL 3407910 T3 PL3407910 T3 PL 3407910T3
- Authority
- PL
- Poland
- Prior art keywords
- mva
- equine encephalitis
- modified vaccinia
- recombinant modified
- ankara
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12141—Use of virus, viral particle or viral elements as a vector
- C12N2720/12143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16153394 | 2016-01-29 | ||
| EP16157055 | 2016-02-24 | ||
| EP16185012 | 2016-08-19 | ||
| PCT/EP2017/051807 WO2017129765A1 (en) | 2016-01-29 | 2017-01-27 | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3407910T3 true PL3407910T3 (pl) | 2022-08-16 |
Family
ID=57960428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17702827.1T PL3407910T3 (pl) | 2016-01-29 | 2017-01-27 | Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10881725B2 (pl) |
| EP (1) | EP3407910B1 (pl) |
| DK (1) | DK3407910T3 (pl) |
| ES (1) | ES2921605T3 (pl) |
| HU (1) | HUE059343T2 (pl) |
| PL (1) | PL3407910T3 (pl) |
| WO (1) | WO2017129765A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| WO2017129765A1 (en) * | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
| US10736962B2 (en) | 2016-02-25 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors |
| US10512662B2 (en) | 2016-02-25 | 2019-12-24 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| EP3847246A1 (en) | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
| WO2021242961A1 (en) * | 2020-05-27 | 2021-12-02 | Vanderbilt University | Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor |
| CN113717951A (zh) * | 2021-08-05 | 2021-11-30 | 中国科学院武汉病毒研究所 | 一种基于马脑炎病毒的溶瘤病毒及其用途 |
| US11510975B1 (en) * | 2021-11-29 | 2022-11-29 | Replicate Bioscience, Inc. | Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses |
| EP4677076A1 (en) | 2023-03-10 | 2026-01-14 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
| EP4677074A1 (en) | 2023-03-10 | 2026-01-14 | Bavarian Nordic A/S | Production of poxviruses from quail cell cultures |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| DE69920192T2 (de) | 1998-03-27 | 2005-09-29 | The Secretary Of State For Defence, Salisbury | Rekombinantes virus |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| CN1250731C (zh) | 2000-08-29 | 2006-04-12 | 惠氏控股公司 | 正链rna病毒复制子颗粒的包装 |
| CN101676389A (zh) | 2000-11-23 | 2010-03-24 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
| US6800289B2 (en) | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
| AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| PL218318B1 (pl) * | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
| ES2222095B1 (es) | 2003-07-02 | 2005-11-16 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia | Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones. |
| US7998733B2 (en) | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| WO2008101349A1 (en) | 2007-02-23 | 2008-08-28 | Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence | Recombinant viral vectors for prevention and protection against alphavirus infection |
| WO2010060632A1 (en) | 2008-11-27 | 2010-06-03 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| WO2012048817A2 (en) | 2010-10-15 | 2012-04-19 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara influenza vaccine |
| WO2013151567A1 (en) | 2012-04-04 | 2013-10-10 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research Institute Of Infectious Diseases | Equine encephalitis virus vaccines and methods of using thereof |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014063832A1 (en) | 2012-10-28 | 2014-05-01 | Bavarian Nordig A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| WO2017129765A1 (en) * | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
-
2017
- 2017-01-27 WO PCT/EP2017/051807 patent/WO2017129765A1/en not_active Ceased
- 2017-01-27 PL PL17702827.1T patent/PL3407910T3/pl unknown
- 2017-01-27 EP EP17702827.1A patent/EP3407910B1/en active Active
- 2017-01-27 ES ES17702827T patent/ES2921605T3/es active Active
- 2017-01-27 US US16/073,434 patent/US10881725B2/en active Active
- 2017-01-27 HU HUE17702827A patent/HUE059343T2/hu unknown
- 2017-01-27 DK DK17702827.1T patent/DK3407910T3/da active
-
2021
- 2021-01-04 US US17/140,357 patent/US11571471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190038739A1 (en) | 2019-02-07 |
| HUE059343T2 (hu) | 2022-11-28 |
| US10881725B2 (en) | 2021-01-05 |
| DK3407910T3 (da) | 2022-07-18 |
| ES2921605T3 (es) | 2022-08-30 |
| EP3407910B1 (en) | 2022-04-13 |
| WO2017129765A1 (en) | 2017-08-03 |
| US11571471B2 (en) | 2023-02-07 |
| US20210205439A1 (en) | 2021-07-08 |
| EP3407910A1 (en) | 2018-12-05 |
| CA3009928A1 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290052A (en) | Recombinantly modified vaccinia ankara virus filovirus vaccine | |
| HUE059343T2 (hu) | Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag | |
| IL263373A (en) | Genetically modified vaccinia virus, compositions containing same and uses thereof | |
| SG11201803474UA (en) | Vaccines against hepatitis b virus | |
| SG10201913630YA (en) | Zika virus vaccine | |
| PL3718565T3 (pl) | Szczepionki przeciwko wirusom układu oddechowego | |
| WO2016144564A9 (en) | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors | |
| ZA201801091B (en) | Recombinant orf virus vector | |
| IL263550A (en) | Infectious bronchitis virus vaccine | |
| SI3534936T1 (sl) | Tolerogeno DNK cepivo | |
| EP3365005C0 (en) | MOPEIA RECOMBINANT VIRUS AND VACCINE PLATFORM | |
| IL254698A0 (en) | A vaccine based on the recombinant Jarl Lin mumps virus 2 | |
| IL258056A (en) | Foxm1-derived peptide and a component containing it | |
| SG11201808268UA (en) | Recombinant hansenula-based high dosage hepatitis b vaccine | |
| PT3407910T (pt) | Vacina contra o vírus da encefalite equina à base de vírus vaccinia ankara modificado (mva) recombinante | |
| GB201702193D0 (en) | Hepatitis E virus vaccine | |
| HK1234648A1 (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
| HK1246161A1 (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
| GB201615311D0 (en) | Virus, Vaccine cures | |
| IL258107A (en) | Peptide derivative - mphosph1 and a component containing it | |
| GB201706600D0 (en) | Virus preparations | |
| HK40010574A (en) | Viral vaccines | |
| GB201507529D0 (en) | Virus preparations | |
| HK1259941A1 (en) | Respiratory virus vaccines | |
| AU2016903295A0 (en) | Viral Vaccines |